Posted by Michael Wonder on 03 Feb 2021
BioCryst announces FDA approval of supplemental new drug application for Rapivab expanding patient population to include children six months and older
3 February 2021 - BioCryst Pharmaceuticals today announced that the U.S. FDA has approved a supplemental new drug application for Rapivab (peramivir injection) expanding the patient population of Rapivab for the treatment of acute uncomplicated influenza to include patients six months and older who have been symptomatic for no more than two days.
Prior to this approval, Rapivab had been indicated for patients two years and older.
